Trial Profile

A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 13 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Axicabtagene ciloleucel (Primary) ; Atezolizumab; Cyclophosphamide; Fludarabine
Indications Diffuse large B cell lymphoma
Focus Adverse reactions; Therapeutic Use
Acronyms ZUMA-6
Sponsors Kite Pharma

Most Recent Events

13 Feb 2024 Number of treatment arms are increased from 1 to 4 by the addition of separate arms for 2 more cohorts in Phase 1 part and an arm for the phase 2 part.
31 Jan 2023 Status changed from active, no longer recruiting to completed.
18 Nov 2022 Planned End Date changed from 1 Sep 2022 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com